Company to Discuss its Ongoing Pivotal Phase III Study in Primary Liver Cancer and its Phase I/II Clinical Study in Ovarian Cancer
LAWRENCEVILLE, N.J., April 12, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (CLSN), an oncology drug development company, today announced that Michael Tardugno, Chairman, President and Chief Executive Officer and Jeffrey Church, Executive Vice President and Chief Financial Officer, will attend the following upcoming investor conferences:
- The ThinkEquity Conference on Thursday, May 2, 2019 at The Mandarin Oriental Hotel in New York City.
- The Deutsche Bank 44th Annual Health Care Conference on Tuesday, May 7, 2019 and Wednesday, May 8, 2019 at The InterContinental Hotel in Boston.
A webcast of Celsion’s presentation at the ThinkEquity Conference may be accessed by visiting the “News & Investors” section of Celsion’s corporate website at www.celsion.com. The format of the Deutsche Bank Health Care Conference will only be comprised of one-on-one and small group meetings with leading institutional investors.
About Celsion Corporation
Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in development for other cancer indications. The Company’s product pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. For more information on Celsion, visit our website: http://www.celsion.com. (CLSN-FIN).
ThermoDox® is a registered trademark of Celsion Corporation.
Celsion Investor Contact
Jeffrey W. Church
Executive Vice President & CFO